Imuraya Group Company Limited operates within the Candy & other confectionery products sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Imuraya Group Company Limited with three other
bakery and confectionary companies in Asia:
GlaxoSmithKline Consumer Healthcare Limited
sales of 43.17 billion Indian Rupees [US$595.25 million]
of which 100%
Ismail Industries Limited
(23.91 billion Pakistan Rupees [US$170.93 million]
of which 78%
was Food Processing), and
Nakamuraya Co., Ltd.
(41.36 billion Japanese Yen [US$364.78 million]
of which 74%
was Confectionery Business).
During the year ended March of 2018, sales at
Imuraya Group Company Limited were ¥45.06 billion (US$397.44 million).
increase of 7.3%
versus 2017, when the company's sales were ¥42.00 billion.
This was the fifth consecutive year of sales increases at Imuraya Group Company Limited
(and since 2013, sales have increased a total of 34%).
Sales of Seasonings Business saw an increase
9.3% in 2018, from
¥4.89 billion to ¥5.35 billion.
Not all segments of Imuraya Group Company Limited experienced an increase in sales in 2018:
sales of Other Businesses fell 2.5% to ¥228.75 million.
(However, this segment's sales were only a very small portion of the company's overall sales).